{"id":3451,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1992-01-22","marketCap":82848.6,"name":"Gilead Sciences Inc","phone":"16505743000","outstanding":1246.97,"symbol":"GILD","website":"https://www.gilead.com/","industry":"Biotechnology"},"price":65.0425,"year":2024,"month":5,"day":4,"weekday":"Saturday","title":"Historical Performance of Gilead Sciences Inc Stock Compared to Industry Benchmarks","date":"2024-05-04","url":"/posts/2024/05/04/GILD","content":[{"section":"1. Overview of Gilead Sciences Inc","text":"Gilead Sciences Inc is a biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative medicines. It focuses on treating and preventing infectious diseases, including HIV/AIDS, hepatitis, and influenza, as well as liver diseases, cancer, and immune-inflammatory diseases. Gilead Sciences Inc. is listed on the NASDAQ stock exchange under the ticker symbol GILD."},{"section":"2. Selection of Industry Benchmarks","text":"For the purpose of comparing performance, we have selected industry benchmarks that closely relate to Gilead Sciences Inc's field of operations. These benchmarks include the iShares NASDAQ Biotechnology ETF (IBB) and the S\u0026P 500 Healthcare Index."},{"section":"3. Assessment of Historical Stock Performance","text":"The historical performance of Gilead Sciences Inc stock has experienced notable fluctuations over the analyzed period. From 2016 to 2021, the stock price generally trended upwards, reaching its peak in 2015. However, it subsequently experienced a significant decline, primarily due to challenges in sustaining the growth of its hepatitis C franchise."},{"section":"4. Comparison with Industry Benchmarks","text":"Gilead Sciences Inc's performance compared to industry benchmarks has been mixed. In some periods, the stock has outperformed the benchmarks, whereas in others, it has lagged behind. This can be attributed to various factors, including market conditions, product performance, and competitive landscape within the biopharmaceutical industry."},{"section":"5. Key Factors Influencing Performance","text":"Several factors have influenced Gilead Sciences Inc's historical performance. These include the success or failure of its drug development pipeline, patent expirations, regulatory approvals, pricing pressures, and competition from generic drugs. Additionally, macroeconomic factors, such as changes in healthcare policies and market sentiment towards the biopharmaceutical sector, have also impacted the stock's performance."},{"section":"6. Recent Developments","text":"Recent developments such as the COVID-19 pandemic and Gilead Sciences Inc's involvement in developing remdesivir as a potential treatment have had a profound impact on the stock's performance. The demand for remdesivir initially boosted investor confidence, resulting in a positive stock performance. However, the stock price has also been subject to fluctuations based on market dynamics and evolving news related to the pandemic."},{"section":"7. Financial Metrics and Ratios","text":"To provide further context, analyzing financial metrics and ratios such as revenue growth, net income, earnings per share, and price-to-earnings ratio can help assess the financial health and valuation of Gilead Sciences Inc. These figures should be considered in conjunction with the overall industry and market conditions to form a comprehensive perspective of the stock's historical performance."},{"section":"8. Conclusion","text":"In conclusion, the historical performance of Gilead Sciences Inc stock has been influenced by various internal and external factors. While it has experienced periods of growth and outperformance compared to industry benchmarks, it has also faced challenges that have resulted in stock price declines. Comprehensive analysis of financial metrics and industry dynamics is crucial in understanding the overall performance of Gilead Sciences Inc stock."}],"tags":["OverSold","Long","Biotechnology"],"news":[{"category":"company","date":1714759200,"headline":"Forbes Has Listed Gilead as One of America’s Best Employers for Diversity","id":127429762,"image":"https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613","symbol":"GILD","publisher":"Yahoo","summary":"NORTHAMPTON, MA / ACCESSWIRE / May 3, 2024 / Gilead Sciences Forbes has listed Gilead as one of America's Best Employers for Diversity. We believe that by championing inclusion and diversity, we not only enrich our workplace but also drive groundbreaking ...","url":"https://finance.yahoo.com/news/forbes-listed-gilead-one-america-180000924.html"},{"category":"company","date":1714732440,"headline":"Interesting GILD Put And Call Options For June 14th","id":127421892,"image":"","symbol":"GILD","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3476089262"},{"category":"company","date":1714727280,"headline":"The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine","id":127417109,"image":"https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.","url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-090800332.html"},{"category":"company","date":1714658520,"headline":"Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News \u0026 More","id":127384417,"image":"https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","symbol":"GILD","publisher":"Yahoo","summary":"Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.","url":"https://finance.yahoo.com/news/biotech-stock-roundup-gilds-gsk-140200793.html"},{"category":"company","date":1714639260,"headline":"Analysts’ Top Healthcare Picks: Bio-Techne (TECH), Gilead Sciences (GILD)","id":127385033,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3473467442"},{"category":"company","date":1714567560,"headline":"IN BRIEF: Guild joins sim racing championship ESL R1","id":127356568,"image":"","symbol":"GILD","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=wouye0c2pb"},{"category":"company","date":1714553340,"headline":"Global company events calendar","id":127351019,"image":"","symbol":"GILD","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=g8v86j4xn7"},{"category":"company","date":1714528620,"headline":"Guild Esports Speeds into ESL R1 Championship","id":127356571,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3470755824"},{"category":"company","date":1714527780,"headline":"Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar","id":127356080,"image":"","symbol":"GILD","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3471684231"},{"category":"company","date":1714507500,"headline":"Gilead Sciences to Present at Upcoming Investor Conferences","id":127331246,"image":"https://s.yimg.com/ny/api/res/1.2/X1iRCEBuVlnorrLnHHRAJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/e3b9627c14b2f95d57768309aaefd6ed","symbol":"GILD","publisher":"Yahoo","summary":"FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:","url":"https://finance.yahoo.com/news/gilead-sciences-present-upcoming-investor-200500761.html"},{"category":"company","date":1714492889,"headline":"Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript","id":127331248,"image":"https://s.yimg.com/ny/api/res/1.2/Hf3etvA0lJHPicbedFHsVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript April 25, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and […]","url":"https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-160129172.html"},{"category":"company","date":1714489419,"headline":"XBI: The 2 Things Biotech Needs To Move Higher","id":127325081,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/470318136/image_470318136.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"See what has influenced volatility of the biotech sector and learn about the key factors that will shape SPDRÂ® S\u0026P Biotech ETF performance. Click for my XBI update.","url":"https://seekingalpha.com/article/4687637-xbi-the-two-things-biotech-needs-to-move-higher"},{"category":"company","date":1714473060,"headline":"Gilead Sciences Enters Oversold Territory","id":127327247,"image":"","symbol":"GILD","publisher":"Dividend Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3469292004"},{"category":"company","date":1714456620,"headline":"Gilead Sciences: Hold Rating Justified Amid Stable Outlook and Upcoming Oncology Catalysts","id":127323846,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3468917390"},{"category":"company","date":1714455240,"headline":"Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)","id":127324083,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3468895718"},{"category":"company","date":1714442460,"headline":"Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)","id":127327254,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3468723401"},{"category":"company","date":1714441920,"headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), R1 RCM (RCM) and Gilead Sciences (GILD)","id":127327256,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3468715949"},{"category":"company","date":1714440780,"headline":"Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)","id":127327257,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3468701597"},{"category":"company","date":1714395610,"headline":"Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It","id":127297711,"image":"https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9","symbol":"GILD","publisher":"Yahoo","summary":"Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.","url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-trending-130010648.html"},{"category":"company","date":1714395360,"headline":"Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week","id":127295214,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3466852434"},{"category":"company","date":1714384875,"headline":"Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data","id":127294719,"image":"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/04/shutterstock_1718136397.jpg","symbol":"GILD","publisher":"Yahoo","summary":"The expanded approval of Gilead’s Biktarvy was based on the Phase I trial data showing efficacy in pregnant HIV patients with suppressed viral loads.","url":"https://www.clinicaltrialsarena.com/news/gilead-expands-fda-label-for-biktarvy-with-phase-i-pregnant-hiv-patient-data/"},{"category":"company","date":1714366140,"headline":"Gilead price target lowered by $4 at Barclays, here's why","id":127304174,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3467000258"},{"category":"company","date":1714365960,"headline":"Gilead Sciences: Hold Rating with Cautious Outlook Amidst Market Challenges and Growth Uncertainties","id":127302243,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3466998392"},{"category":"company","date":1714228164,"headline":"Gilead Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags","id":127272522,"image":"https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences ( NASDAQ:GILD ) First Quarter 2024 Results Key Financial Results Revenue: US$6.69b (up 5.3% from 1Q...","url":"https://finance.yahoo.com/news/gilead-sciences-first-quarter-2024-142924994.html"},{"category":"company","date":1714185660,"headline":"Amgen’s Blincyto data send Cullinan higher","id":127276940,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3465503895"},{"category":"company","date":1714148267,"headline":"Gilead Gives Up Big Gains As Covid Drug Drives Its Beat — Again","id":127249543,"image":"https://media.zenfs.com/en/ibd.com/7ce26b4b87cc5cc7683c1900afb4c75b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.","url":"https://finance.yahoo.com/m/a7f6d37a-39c1-39c8-9f9a-e22c82514dfd/gilead-gives-up-big-gains-as.html"},{"category":"company","date":1714141440,"headline":"Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat","id":127249545,"image":"https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629","symbol":"GILD","publisher":"Yahoo","summary":"Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.","url":"https://finance.yahoo.com/news/gilead-gild-q1-loss-narrower-142400219.html"},{"category":"company","date":1714133463,"headline":"Q1 2024 Gilead Sciences Inc Earnings Call","id":127244230,"image":"","symbol":"GILD","publisher":"Yahoo","summary":"Q1 2024 Gilead Sciences Inc Earnings Call","url":"https://finance.yahoo.com/news/q1-2024-gilead-sciences-inc-121103209.html"},{"category":"company","date":1714132800,"headline":"FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV","id":127244231,"image":"https://s.yimg.com/ny/api/res/1.2/QzTNW33.tVGNKqRmX76ztg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/701a162d3e721bc78a02e966b681d24f","symbol":"GILD","publisher":"Yahoo","summary":"FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of","url":"https://finance.yahoo.com/news/fda-approves-biktarvy-label-data-120000380.html"},{"category":"company","date":1714130460,"headline":"Analysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)","id":127272593,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3464814641"},{"category":"company","date":1714129860,"headline":"June 7th Options Now Available For Gilead Sciences (GILD)","id":127255621,"image":"","symbol":"GILD","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463612010"},{"category":"company","date":1714128540,"headline":"3 Dividend Stocks to Buy at a 52-Week Low in April","id":127249920,"image":"","symbol":"GILD","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463578600"},{"category":"company","date":1714123800,"headline":"Gilead Sciences declares $0.77 dividend","id":127255623,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463461077"},{"category":"company","date":1714117680,"headline":"Gilead price target lowered by $5 at TD Cowen, here's why","id":127255625,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463319859"},{"category":"company","date":1714116900,"headline":"Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...","id":127244232,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"GILD","publisher":"Yahoo","summary":"Explore Gilead's latest financial performance and strategic directions, including updates on HIV, oncology, and liver disease segments.","url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-q1-073500074.html"},{"category":"company","date":1714116360,"headline":"Gilead announces FDA approval for updated Biktarvy label","id":127255626,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463290982"},{"category":"company","date":1714116120,"headline":"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)","id":127255627,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463286580"},{"category":"company","date":1714115160,"headline":"Gilead price target lowered by $2 at RBC Capital, here's why","id":127255628,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463267383"},{"category":"company","date":1714114260,"headline":"Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)","id":127255629,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463249977"},{"category":"company","date":1714113060,"headline":"Truist Financial Reaffirms Their Hold Rating on Gilead Sciences (GILD)","id":127255631,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463228043"},{"category":"company","date":1714112820,"headline":"Gilead Sciences: A Strong Buy on Robust Sales and Promising Future Catalysts","id":127255634,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463222309"},{"category":"company","date":1714110540,"headline":"Gilead Sciences grows sales and dividend but lowers some guidance","id":127255635,"image":"","symbol":"GILD","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=5em9695z1q"},{"category":"company","date":1714110120,"headline":"Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)","id":127255636,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463176471"},{"category":"company","date":1714109460,"headline":"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck \u0026 Company (MRK)","id":127255637,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463167286"},{"category":"company","date":1714097940,"headline":"Gilead Sciences Unusual Options Activity","id":127255638,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3463917239"},{"category":"company","date":1714095915,"headline":"Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript","id":127236507,"image":"https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg","symbol":"GILD","publisher":"Yahoo","summary":"GILD earnings call for the period ending March 31, 2024.","url":"https://www.fool.com/earnings/call-transcripts/2024/04/25/gilead-sciences-gild-q1-2024-earnings-call-transcr/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1714082408,"headline":"Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say","id":127236508,"image":"https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba","symbol":"GILD","publisher":"Yahoo","summary":"Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.","url":"https://finance.yahoo.com/news/gilead-gild-reports-q1-earnings-220008000.html"},{"category":"company","date":1714081740,"headline":"Gilead Beats Earnings Expectations After Rocky Quarter","id":127236509,"image":"","symbol":"GILD","publisher":"Yahoo","summary":"The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.","url":"https://finance.yahoo.com/m/219ac92c-47c2-3ee8-8a83-f7bb3539b573/gilead-beats-earnings.html"},{"category":"company","date":1714081311,"headline":"Gilead Sciences Inc (GILD) Q1 2024 Earnings: Misses Analyst EPS Estimates Amid Significant ...","id":127236510,"image":"","symbol":"GILD","publisher":"Yahoo","summary":"Comprehensive Analysis of Gilead's First Quarter Financial Performance","url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-q1-214151392.html"},{"category":"company","date":1714079703,"headline":"Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates","id":127236511,"image":"https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39","symbol":"GILD","publisher":"Yahoo","summary":"Gilead (GILD) delivered earnings and revenue surprises of 11.41% and 5.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?","url":"https://finance.yahoo.com/news/gilead-sciences-gild-reports-q1-211503328.html"},{"category":"company","date":1714077647,"headline":"Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again","id":127236512,"image":"https://media.zenfs.com/en/ibd.com/7ce26b4b87cc5cc7683c1900afb4c75b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury. And Gilead stock jumped in late trades Thursday.","url":"https://finance.yahoo.com/m/a7f6d37a-39c1-39c8-9f9a-e22c82514dfd/gilead-notches-a-quarterly.html"},{"category":"company","date":1714076765,"headline":"Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript","id":127229115,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"GILD","publisher":"SeekingAlpha","summary":"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ETCompany ParticipantsJacquie Ross - Vice President,...","url":"https://seekingalpha.com/article/4686465-gilead-sciences-inc-gild-q1-2024-earnings-call-transcript"},{"category":"company","date":1714076074,"headline":"Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation","id":127228817,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"GILD","publisher":"SeekingAlpha","summary":"The following slide deck was published by Gilead Sciences, Inc.","url":"https://seekingalpha.com/article/4686461-gilead-sciences-inc-2024-q1-results-earnings-call-presentation"},{"category":"company","date":1714075896,"headline":"Gilead posts quarterly loss, revenue rises 5%","id":127221676,"image":"https://media.zenfs.com/en/reuters-finance.com/de6fddb5dde53d7945a8f1ba1f40c5c6","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales.  For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the recent charge as well as incremental expenses related to the CymaBay deal.  Wall Street analysts currently project Gilead's 2024 earnings at $3.94 a share on revenue of $27.5 billion, according to LSEG data.","url":"https://finance.yahoo.com/news/gilead-posts-quarterly-loss-revenue-201136712.html"},{"category":"company","date":1714075667,"headline":"Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?","id":127221677,"image":"https://media.zenfs.com/en/ibd.com/7ce26b4b87cc5cc7683c1900afb4c75b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury. And Gilead stock could take hit Thursday.","url":"https://finance.yahoo.com/m/a7f6d37a-39c1-39c8-9f9a-e22c82514dfd/will-gilead%27s-big-veklury.html"},{"category":"company","date":1714075320,"headline":"Gilead Sciences Announces First Quarter 2024 Financial Results","id":127236513,"image":"https://s.yimg.com/ny/api/res/1.2/QzvA2mAO.cOV0jt1HNKDVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/80c16dd2d9946946e8ecdf2ecc03f9b7","symbol":"GILD","publisher":"Yahoo","summary":"FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.","url":"https://finance.yahoo.com/news/gilead-sciences-announces-first-quarter-200200212.html"},{"category":"company","date":1714067356,"headline":"These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)","id":127224862,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482998631/image_1482998631.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"The Annual Meeting of ASCO is a major event for clinicians and researchers in the field of oncology. Explore more details here.","url":"https://seekingalpha.com/article/4686392-these-are-the-biotechs-showing-up-at-the-biggest-cancer-meeting-of-the-year-oral-presentations"},{"category":"company","date":1714063225,"headline":"Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges","id":127222465,"image":"","symbol":"GILD","publisher":"Finnhub","summary":"By Paul Ziobro Gilead Sciences posted higher first-quarter sales, but swung to a steep loss due to charges related to recent acquisitions, prompting the company to cut its per-share profit...","url":"https://finnhub.io/api/news?id=f865e37d2899cba02ae2686220b306f9b1bb6c7b061de8ff24b2a9cf7ca8b84b"},{"category":"company","date":1714061719,"headline":"Gilead: Q1 Earnings Snapshot","id":127221661,"image":"","symbol":"GILD","publisher":"Finnhub","summary":"FOSTER CITY, Calif. — FOSTER CITY, Calif. — Gilead Sciences Inc. on Thursday reported a loss of $4.17 billion in its first quarter. The Foster City, California-based company said it had a...","url":"https://finnhub.io/api/news?id=2c782baf03729c4ef97c9446ed58f55a736a69c1e3884d716db115a02b2db09f"},{"category":"company","date":1714048680,"headline":"Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?","id":127217773,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461617283"},{"category":"company","date":1714046940,"headline":"Notable companies reporting after market close","id":127217774,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461565985"},{"category":"company","date":1714034580,"headline":"Gilead’s quarterly loss is narrower than expected","id":127255640,"image":"","symbol":"GILD","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3462569985"},{"category":"company","date":1714032600,"headline":"March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys","id":127210189,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503371245/image_1503371245.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Portfolio changes in March focus on BDCs, aiming to increase dividend income by at least $100 each month. Click here for a detailed analysis.","url":"https://seekingalpha.com/article/4685904-marchs-dividend-portfolio-update-sets-new-all-time-record-100-holdings-21-buys"},{"category":"company","date":1714032000,"headline":"Polaris Global Equity Composite Q1 2024 Commentary","id":127210034,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303046106/image_1303046106.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Global equity markets enjoyed consecutive months of gains, with the MSCI World Index returning 9.01% for the quarter.","url":"https://seekingalpha.com/article/4686064-polaris-global-equity-composite-q1-2024-commentary"},{"category":"company","date":1714029660,"headline":"Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)","id":127226767,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461103653"},{"category":"company","date":1714028160,"headline":"GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024","id":127255643,"image":"","symbol":"GILD","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3462347095"},{"category":"company","date":1714025160,"headline":"Options Volatility and Implied Earnings Moves Today, April 25, 2024","id":127215905,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461010840"},{"category":"company","date":1714024800,"headline":"Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus","id":127226773,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3462231561"},{"category":"company","date":1714022580,"headline":"US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst","id":127214601,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3460967585"},{"category":"company","date":1714018920,"headline":"Fly Intel: After-Hours Movers","id":127224374,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3462032123"},{"category":"company","date":1714015620,"headline":"Gilead Sciences in charts: Revenue from oncology rises most among products; Veklury dips in Q1","id":127226778,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461918546"},{"category":"company","date":1714014540,"headline":"Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M","id":127226779,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461885074"},{"category":"company","date":1714014240,"headline":"Gilead cuts FY24 adjusted EPS view to $3.45-$3.85 from $6.85-$7.25","id":127226780,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461878029"},{"category":"company","date":1714014180,"headline":"Gilead reports Q1 adjusted EPS ($1.32), consensus ($1.39)","id":127226781,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461876422"},{"category":"company","date":1714011540,"headline":"Gilead options imply 3.2% move in share price post-earnings","id":127226782,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461797333"},{"category":"company","date":1713983312,"headline":"Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.","id":127194571,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Discover the impact of the Inflation Reduction Act on generic drugs, benefiting certain stocks in the pharmaceutical sector. Click here to read an analysis on VTRS stock now.","url":"https://seekingalpha.com/article/4685874-inflation-reduction-act-a-bullish-catalyst-for-viatris"},{"category":"company","date":1713964740,"headline":"What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?","id":127184290,"image":"https://media.zenfs.com/en/zacks.com/12dfb060a52eb196f98ee11cc492ea9d","symbol":"GILD","publisher":"Yahoo","summary":"Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.","url":"https://finance.yahoo.com/news/whats-store-5-pharma-bigwigs-131900428.html"},{"category":"company","date":1713963750,"headline":"Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage","id":127185874,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1483000268/image_1483000268.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Madrigal recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. Check out my analysis of MDGL stock here.","url":"https://seekingalpha.com/article/4685718-madrigal-2-challenges-to-overcome-to-maintain-nash-first-mover-advantage"},{"category":"company","date":1713961620,"headline":"HSBC gets more bullish on Gilead, upgrades shares","id":127195874,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459494309"},{"category":"company","date":1713921120,"headline":"Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus","id":127195877,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459566589"},{"category":"company","date":1713880863,"headline":"Incyte (INCY) Earnings Expected to Grow: Should You Buy?","id":127161901,"image":"https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248","symbol":"GILD","publisher":"Yahoo","summary":"Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","url":"https://finance.yahoo.com/news/incyte-incy-earnings-expected-grow-140103175.html"},{"category":"company","date":1713877968,"headline":"3 Potential Biopharma Buyout Targets","id":127161456,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1479134763/image_1479134763.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M\u0026A volume in the coming year. Click here to read our picks.","url":"https://seekingalpha.com/article/4685355-3-potential-biopharma-buyout-targets"},{"category":"company","date":1713862803,"headline":"Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?","id":127157381,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1319956561/image_1319956561.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Check out whether GILD stock is a good buy ahead of Q1 earnings.","url":"https://seekingalpha.com/article/4685264-gilead-q1-earnings-preview-most-gains-wiped-out-cause-for-concern"},{"category":"company","date":1713809984,"headline":"Undervalued Icons: 3 Household Names Trading at Steep Discounts","id":127286106,"image":"https://media.zenfs.com/en/investorplace_417/ec0fb27b2f971f6013ac12286bb180e3","symbol":"GILD","publisher":"Yahoo","summary":"Among Wall Street stocks, some of the best opportunities can be found in reliable companies trading at a discount. With such undervalued stocks, investors get a strong foundation for their portfolio along with potential for positive returns. While the allure of high-flying startups is undeniable, there’s a certain comfort in established companies with a proven history of success. These household names offer a sense of stability and often provide reliable dividends alongside the possibility for l","url":"https://finance.yahoo.com/news/undervalued-icons-3-household-names-181944454.html"},{"category":"company","date":1713808620,"headline":"Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?","id":127151902,"image":"https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619","symbol":"GILD","publisher":"Yahoo","summary":"Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.","url":"https://finance.yahoo.com/news/gilead-gild-gears-report-q1-175700025.html"},{"category":"company","date":1713798248,"headline":"Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value","id":127141693,"image":"https://media.gettyimages.com/id/2149039460/photo/experiment-microscope-and-sample-with-woman-scientist-in-laboratory-for-breakthrough-or.jpg?b=1\u0026s=170667a\u0026w=0\u0026k=20\u0026c=CzEScWG8q2mRtxzFeirj6FClEnd5-mHw4SxazGvMY8E=","symbol":"GILD","publisher":"SeekingAlpha","summary":"FDA approved Mirum Pharmaceuticals' Limvarli for treatment of cholestatic pruritus in patients with PFIC. Learn why I rate MIRM stock a buy.","url":"https://seekingalpha.com/article/4685141-mirum-pharmaceuticals-mirm-phase-2-miss-ibat-inhibitor-drive-value"},{"category":"company","date":1713795623,"headline":"Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts","id":127140770,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1350525671/image_1350525671.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Hookipa Pharma's positive data could push shares up 3-5x while negative news could cut the stock in half or worse. Check out more on HOOK stock here.","url":"https://seekingalpha.com/article/4685130-hookipa-pharma-042524-update-should-be-the-first-of-several-positive-catalysts"},{"category":"company","date":1713791765,"headline":"Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics","id":127142064,"image":"https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85","symbol":"GILD","publisher":"Yahoo","summary":"Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.","url":"https://finance.yahoo.com/news/insights-gilead-gild-q1-wall-131605255.html"},{"category":"company","date":1713791083,"headline":"Be Greedy When Others Are Fearful, Even If They Are Fearful For A Good Reason","id":127139082,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398379170/image_1398379170.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Investors caught off guard by increased geopolitical risk may face short-term selling pressure, potentially worsening the S\u0026P 500's drawdown. Read here for details.","url":"https://seekingalpha.com/article/4685108-be-greedy-when-others-are-fearful-even-if-they-are-fearful-for-a-good-reason"},{"category":"company","date":1713787380,"headline":"Gilead Sciences: Some Signs Of An Impending Bottom","id":127137976,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1129163219/image_1129163219.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Gilead Sciencesâ stock underperformed market substantially over past decade. It offers a high 4.61% dividend yield. Read my earnings analysis of GILD stock here.","url":"https://seekingalpha.com/article/4685090-gilead-sciences-some-signs-of-an-impending-bottom"},{"category":"company","date":1713683100,"headline":"Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more","id":127128647,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3454493428"},{"category":"company","date":1713614580,"headline":"THQ: Collecting A High Yield From Increased Medical Spending","id":127119950,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1868353991/image_1868353991.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield and exposure to diverse healthcare subsectors, outperforming peers. Explore more here.","url":"https://seekingalpha.com/article/4684905-thq-collecting-a-high-yield-from-increased-medical-spending-cef"}]}